However, a recent study by Xiong et al showed that PCK2 expression inhibited the progression of renal cell carcinoma (RCC) and enhanced RCC sensitivity to sunitinib [25]. This evidence concerns the gene PCK2 and hereditary clear cell renal cell carcinoma.